The case for genetically selecting or editing embryos rests on a straightforward idea: if we can prevent serious suffering before a child is born, there are strong reasons to do so. The term “designer babies” covers a spectrum of technologies, from screening embryos during IVF to directly editing genes with tools like CRISPR. Each carries different levels of capability and risk, but the potential benefits range from eliminating devastating genetic diseases to reducing long-term healthcare costs by billions of dollars.
Preventing Genetic Diseases Before Birth
The most widely accepted argument for genetic selection involves monogenic diseases, conditions caused by a single faulty gene. Cystic fibrosis, sickle cell disease, Huntington’s disease, and Tay-Sachs all fall into this category. Today, couples who carry these genes can use IVF combined with preimplantation genetic testing (PGT-M) to screen embryos before pregnancy. The technology is remarkably reliable: accuracy rates now exceed 99%, with misdiagnosis occurring in fewer than 1 in 1,000 cases.
For conditions where screening alone isn’t sufficient, gene editing offers a more direct route. CRISPR-based tools can target the specific mutation responsible for a disease and correct it at the embryo stage. Early experiments were hampered by low efficiency and a problem called mosaicism, where only some cells in the embryo were successfully edited. Newer approaches, including base editing and prime editing, have improved precision significantly. Prime editing, a “search-and-replace” technique, doesn’t require cutting both strands of DNA and has shown no detectable off-target mutations in human cells in laboratory studies.
The practical impact is enormous. A child born with cystic fibrosis faces a lifetime of lung infections, daily treatments, and a current life expectancy of roughly 37 years. A child born after successful embryo screening or editing could be entirely free of the disease, with no need for lifelong treatment.
Building In Disease Resistance
Beyond correcting known mutations, genetic technology could give children built-in resistance to infectious diseases. The best-studied example involves a protein on the surface of immune cells that HIV uses as its entry point into the body. About 1% of people with Northern European ancestry carry two copies of a natural mutation (called delta-32) that prevents this protein from appearing on cell surfaces. These individuals are substantially resistant to HIV infection and show no health problems from lacking the protein.
This isn’t theoretical. The mutation already exists in nature and has been studied extensively. Researchers have also identified genetic patterns linked to natural resistance in people who are repeatedly exposed to HIV but never become infected. Engineering this same change into embryos could, in principle, provide innate protection against one of the world’s most persistent epidemics. Similar approaches could eventually target genetic susceptibility to malaria, certain cancers, or other conditions with clear genetic components.
Saving Existing Children Through Savior Siblings
One of the most emotionally compelling uses of embryo selection involves what’s known as a “savior sibling.” When a child has a life-threatening blood disease or immune disorder that requires a stem cell transplant, finding a matched donor can be nearly impossible. IVF with genetic testing allows parents to select an embryo that is both free of the family’s genetic disease and a tissue match for the sick child.
The newborn’s umbilical cord blood, rich in stem cells, can then be used for transplantation. A landmark study documented successful stem cell transplants in 44 children from healthy siblings conceived through this process. The procedure doesn’t harm the donor child, and researchers have noted potential psychological benefits: savior siblings often grow up knowing they played a role in saving their brother’s or sister’s life.
The Economic Case
Genetic disease is staggeringly expensive to manage over a lifetime. The average annual direct medical cost for a single cystic fibrosis patient runs about $63,000. Over a 37-year life expectancy, that adds up to roughly $2.3 million per patient. An IVF cycle with genetic screening costs approximately $57,000 per successful delivery, a one-time expense.
A national program offering IVF with genetic testing to all cystic fibrosis carrier couples (about 4,000 per year in the U.S.) would produce an estimated $2.2 billion in savings annually in avoided lifetime treatment costs. Over 37 years, the cumulative net savings would reach $33.3 billion. And that’s for one disease. Extend the same logic to sickle cell disease, Tay-Sachs, Huntington’s, and dozens of other conditions, and the economic argument becomes difficult to dismiss. Those savings also represent something money can’t fully capture: millions of hours not spent in hospitals, not enduring painful treatments, not navigating disability.
The Philosophical Argument for Selection
Philosopher Julian Savulescu formalized the ethical case with what he calls the Principle of Procreative Beneficence. The core claim is simple: if parents have the ability to select or create embryos with the best chance at a healthy, flourishing life, they have a moral reason to do so. This isn’t about creating “perfect” children. It’s about the idea that, given the choice between an embryo carrying a gene for a painful degenerative disease and one without it, choosing health is not just permissible but arguably obligatory.
Critics worry this slides toward eugenics, and that concern deserves serious weight. But proponents draw a clear line: the goal is reducing suffering, not enforcing uniformity. Parents already make choices that shape their children’s futures, from nutrition during pregnancy to education. Genetic selection, in this view, is an extension of the same parental instinct to give children the best possible start.
Longer, Healthier Lives
Research into human longevity has identified specific genetic pathways that regulate how quickly we age. One of the most studied involves a group of proteins called FOXO transcription factors, which control genes related to stress response, immune function, and cellular repair. When the signaling pathways that suppress FOXO activity are reduced (through caloric restriction, for instance), the result in animal models is consistently longer lifespan and better stress management.
In humans, six types of these transcription factors have been identified, and variations in related genes are consistently associated with reaching extreme old age. While no one is editing embryos for longevity today, the genetic targets are becoming clearer. The prospect of engineering enhanced cellular repair mechanisms or more resilient stress responses could, over time, shift the average human healthspan by years or decades.
Improving Safety With Better Tools
The strongest practical objection to embryo editing has been safety: what if the editing tool cuts DNA in the wrong place? Early CRISPR experiments did show concerning off-target effects, including large deletions and even loss of entire chromosome segments. But the technology has advanced rapidly.
High-fidelity versions of the core editing protein retain normal cutting ability at the intended site while dramatically reducing errors. One variant, called SpCas9-HF1, maintained on-target performance with more than 85% of the guide sequences tested in human cells while nearly eliminating off-target cuts. An even newer redesign, SuperFi-Cas9, is 4,000 times less likely to cut at the wrong location compared to the original tool. It achieved a 6.3-fold preference for cutting correct DNA versus mismatched DNA, compared to just 1.55-fold for the original version.
Other strategies reduce risk further. Using a “nickase” version of the tool that cuts only one DNA strand instead of both limits collateral damage. Prime editing avoids double-strand breaks entirely. And newer enzymes that require rarer, more specific DNA sequences to bind have a lower probability of latching onto the wrong spot in the genome. None of these innovations makes the technology perfectly safe yet, but the trajectory is clearly toward greater precision.
Where Governance Stands
No country currently permits heritable human genome editing for clinical use. The Third International Summit on Human Genome Editing, held in 2023, concluded that the technology should not be used until it meets reasonable standards for safety and efficacy, is legally authorized, and operates under rigorous oversight. Those conditions have not yet been met.
International bodies have laid out frameworks for how to get there responsibly. The WHO emphasizes values and principles rather than blanket bans, calling for inclusive public deliberation in any country considering clinical use. An international commission recommended oversight at every stage of development, from lab research through clinical application, along with an international scientific advisory panel and a mechanism for raising concerns across borders. The European Group on Ethics has stressed protecting social justice and equality, specifically recommending safeguards against using genome editing for non-health-related trait enhancement.
The picture that emerges is not one of prohibition but of cautious preparation. The scientific and governance communities are building the infrastructure for a future where these technologies could be used responsibly, with broad public input determining when and how that happens.